Apple Watch Blood Oxygen Tracker Back in US

Apple Inc. is restoring the blood oxygen tracking feature on its Apple Watch in the U.S., following its removal in late 2023 due to a patent infringement lawsuit by Masimo Corp. and a US Customs injunction. This reintroduction, facilitated by iOS and watchOS software updates, is strategically significant as it enables Apple to re-market a core health monitoring capability ahead of anticipated new Apple Watch and iPhone model unveilings next month.

Analysis

Apple Inc. (AAPL) is reinstating its blood oxygen tracking feature for US Apple Watch models, resolving a significant product-level issue that stemmed from a patent infringement lawsuit by Masimo Corp. (MASI). The feature, previously removed in late 2023 following a US Customs injunction, is being restored via software updates (iOS 18.6.1 and watchOS 11.6.1) that implement a workaround, displaying the data on a connected iPhone rather than directly within the watch application. This development, viewed as moderately positive for the market and highly positive for Apple specifically (sentiment score: 0.7), is strategically timed. It comes just one month before the company's anticipated new Apple Watch and iPhone 17 launch event, allowing Apple to once again market a key health monitoring capability and strengthen its competitive positioning in the wearables space. For Masimo, this represents a notable setback in its litigation efforts, as reflected by its negative sentiment score (-0.5).

Key Decisions for Investors

• Investors should view this development as a de-risking event for Apple's upcoming product cycle, as it restores a key feature and removes a significant marketing and sales headwind for the Apple Watch division.
• The negative outcome for Masimo Corp. in this customs ruling weakens its litigation leverage against Apple, warranting a re-evaluation of the potential financial upside from its patent claims.
• Monitor the specifics of the software workaround, as its nature may indicate the extent to which Apple has circumvented Masimo's patents, a factor that could influence the ongoing, broader legal dispute.